J Clin Invest. 2022 Feb 1;132(3). doi: 10.1172/JCI154888.
Cellular senescence is a fundamental aging mechanism that is currently the focus of considerable interest as a pathway that could be targeted to ameliorate aging across multiple tissues, including the skeleton. There is now substantial evidence that senescent cells accumulate in the bone microenvironment with aging and that targeting these cells prevents age-related bone loss, at least in mice. Cellular senescence also plays important roles in mediating the skeletal fragility associated with diabetes mellitus, radiation, and chemotherapy. As such, there are ongoing efforts to develop "senolytic" drugs that kill senescent cells by targeting key survival mechanisms in these cells without affecting normal cells. Because senescent cells accumulate across tissues with aging, senolytics offer the attractive possibility of treating multiple age-related comorbidities simultaneously.
细胞衰老(Cellular senescence)是一种基本的衰老机制,目前作为一种可能的途径,受到了极大的关注,这种途径可以改善包括骨骼在内的多种组织的衰老。现在有大量证据表明,衰老细胞会随着年龄的增长而在骨骼微环境中积累,而靶向这些细胞可以防止与年龄相关的骨质流失,至少在小鼠中是这样。细胞衰老在介导与糖尿病、辐射和化疗相关的骨骼脆弱方面也起着重要作用。因此,人们正在努力开发“衰老细胞选择性清除剂(senolytic)”药物,这些药物通过靶向这些细胞中的关键存活机制来杀死衰老细胞,而不影响正常细胞。由于衰老细胞会随着年龄的增长而在多个组织中积累,衰老细胞选择性清除剂为同时治疗多种与年龄相关的共病提供了有吸引力的可能性。